SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008968
Filing Date
2022-05-16
Accepted
2022-05-16 16:22:36
Documents
85
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ganx-20220331x10q.htm   iXBRL 10-Q 1677563
2 EX-31.1 ganx-20220331xex31d1.htm EX-31.1 10931
3 EX-31.2 ganx-20220331xex31d2.htm EX-31.2 10398
4 EX-32.1 ganx-20220331xex32d1.htm EX-32.1 10300
  Complete submission text file 0001558370-22-008968.txt   7151261

Data Files

Seq Description Document Type Size
5 EX-101.SCH ganx-20220331.xsd EX-101.SCH 55605
6 EX-101.CAL ganx-20220331_cal.xml EX-101.CAL 54259
7 EX-101.DEF ganx-20220331_def.xml EX-101.DEF 194561
8 EX-101.LAB ganx-20220331_lab.xml EX-101.LAB 476824
9 EX-101.PRE ganx-20220331_pre.xml EX-101.PRE 367635
79 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20220331x10q_htm.xml XML 1108218
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

IRS No.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40237 | Film No.: 22929516
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences